Search

For mentors

When discussing this career development opportunity with your associates, please keep in mind that applicants with the same mentor are eligible to apply. However, no more than ONE participant from a specific mentor will be selected.

Read more

Mutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?

During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.

Read more

Statement

The European Hematology Association (EHA), a dedicated community of healthcare professionals, who work tirelessly "Towards prevention, cure, and quality of life for all patients with blood disorders", expresses its deep concern and sorrow over the ongoing violence and humanitarian crisis…

Read more

Ukraine Bridge Funding - information for applicants

The EHA Ukraine Bridge Funding Program is a 1-year non-clinical funding opportunity for Ukrainian hematologists and researchers in hematology (see press release here), now in collaboration with the American Society of Hematology, which will participate in funding and the selection…

Read more

Practical information

When do the meetings take place?The Spring Course will take place from 07-14 March 2025 in France. The first follow-up meeting will take place during the EHA2025 Congress from 12 – 15 June 2025.

Read more

SWG Educational Activities

MeetingsEHA SWG EWALL SymposiumLocation and dateThis meeting was held in Frankfurt in June 2023 as part of EHA2023. TopicPersonalized ALL therapy. ChairNicola Gokbuget

Sessions and speakers
B-cell precursor ALL, the Finnish experience (Kimmo Porkka).

Read more

Precision Hematology

Definition: SWG-Precision Hematology focus on precision medicine for malignant hematology.

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more